| dc.description.abstract | Background: Postpartum intrauterine contraceptives device (IUCD) is a reliable, effective, safe and recommended contraceptive method for the postpartum mothers. However, there is limited data regarding the prevalence of use of postpartum IUCD and its determinants among mothers in Lira district. This study aimed to investigate the prevalence and determinants of postpartum IUCD use among postpartum mothers in abori A and B cells in Lira city east division.
Methods: A community-based analytic cross-sectional study was done at Abori Cell A Division in Lira district. Data were collected using pretested researcher-administered questionnaire. The data were coded, cleaned and entered in EpiData and analyzed in the Statistical Package for Social Sciences Research (SPSS) version 20. Univariate, bivariate, and multivariate analysis
were conducted, and the level of statistical significance was set at 5%.
Results: Of 384 participants studied, 37(9.6%) had used postpartum IUCD. The use of postpartum IUCD was independently associated with maternal age ≥35 years (Adjusted odds ratio (aOR), 8.12; 95% confidence interval (CI), 1.30-49.19; p = 0,021), parity ≥3 (aOR, 4.19;95%, 1.78-10.80; p=0.002), at least secondary level of education (aOR, 0.25; 95% CI, 0.07-0.85;
p=0.030), and reporting that IUCD has no adverse effects (aOR, 8.83; 95% CI, 3.91-21.90;p<0.001).
Conclusion: The prevalence of intra-uterine contraceptive device use among postpartum mothers at Abori A and B Cells, Adekokwok ward, Lira City East division was low. Maternal age ≥35, parity ≥3, absence of IUCD adverse effects are associated with increased use of postpartum IUCD while at least secondary level of education is associated with reduced use.
Recommendation: There is a need to provide mothers with correct and accurate information about postpartum IUCD through health education. This will contribute to improving the use of postpartum IUCD in the study area. Contraceptive service providers need toregularly monitor use of postpartum IUCD for adverse side effects and take corrective active as fast as possible. | en_US |
